Tag: Medication

Posted on

ProPure™ Endotoxin-Free Proteins for Reliable Cancer Research

Sponsored content brought to you by

Sino Biological Logo

In cancer research and therapy development, even trace levels of endotoxins (LPS) in recombinant proteins can severely distort results. In discovery and preclinical studies, endotoxins are silent disruptors of animal immunization, sensitive biological assays, and toxicity assessments, compromising results and safety evaluations. Endotoxin-free recombinant proteins are therefore essential for generating reliable research data and successful development of next-generation cancer therapeutics.

Invisible interference in cancer therapy and vaccine development

Endotoxin contamination can severely compromise antibody generation in animal models. Even small amounts of endotoxins can alter the host’s immune response, reducing antibody specificity, consistency, and overall quality. Endotoxin-contaminated recombinant proteins can subtly—but significantly—alter cellular behavior through immunostimulatory and cytotoxic effects. Endotoxin-induced systemic inflammation in animals can further disrupt experiments, potentially leading to study suspension or even termination.

In cell-based studies, endotoxin contamination can be a hidden disruptor. Immune cells such as dendritic cells, macrophages, monocytes, and T cells can respond strongly even to trace amounts of endotoxins, leading to cytokine release, altered proliferation, or unexpected activation. These effects can easily produce misleading or non-reproducible results.

The demand for endotoxin-free reagents is even more critical in the development of cancer vaccines. Since these therapies rely on precise modulation of the immune system, endotoxin contamination can trigger unintended immune activation, masking the true efficacy of the vaccine candidate and introducing safety risks. Using endotoxin-free proteins is therefore vital to accurately evaluate immunogenicity and support safe clinical translation.

Sino Biological’s ProPure™ solution to minimize endotoxin risk

While pharmacopeial guidelines such as USP <85> provide general limits for endotoxin, cutting-edge immunology and translational oncology studies often require far stricter control. Sino Biological’s ProPure endotoxin-free recombinant proteins are designed to eliminate this variable at the source, supporting reliable results from early discovery through IND-enabling studies. Produced at the state-of-the-art Center for Bioprocessing (C4B) in Houston, Texas, ProPure reagents are rigorously controlled to achieve levels as low as 0.05 EU/mg, with select products reaching an exceptional 0.01 EU/mg—over ten times lower than typical industry standards.

By incorporating endotoxin-free proteins, researchers in cancer therapy and vaccine development can confidently achieve consistent and accurate results in critical applications, including:

  • Animal immunization for antibody generation—ensuring high-quality antibodies and predictable host immune responses.
  • Preclinical toxicology and pharmacokinetics (PK)—minimizing confounding immune activation in animal models.
  • In vitro cell proliferation and differentiation assays—reducing false positives caused by endotoxin-sensitive cells such as dendritic cells, macrophages, and T cells.
  • Precise detection and quantification of cytokines—supporting reliable immunological readouts and biomarker analyses.

How ProPure achieves ultra-low endotoxin levels

ProPure quality is not achieved by end-stage cleanup alone. C4B employs an integrated Prevention–Isolation–Detection strategy across the entire production lifecycle.

  • Prevention at the source: Endotoxin-free plasmids and buffers, low endotoxin-binding plastics, and stringent clean-in-place (CIP) procedures minimize endotoxin introduction from cloning through purification.
  • Environmental isolation: The facility follows an E. coli-free principle, eliminating a major source of endotoxin introduction in recombinant protein production.
  • Dual detection: Each batch is tested using Limulus Amebocyte Lysate (LAL) and/or recombinant Factor C (rFC) assays for sensitive, redundant detection, and fully traceable batch data.
ProPure triple-control strategy for ultra-low endotoxin illustration
ProPure triple-control strategy for ultra-low endotoxin.

This end-to-end design ensures that ProPure proteins arrive ready for use in the most demanding oncology and immunology applications, without extra purification steps that can damage protein quality or delay timelines.

With advanced technologies and rigorous quality control, Sino Biological delivers endotoxin-free proteins that meet the needs of highly sensitive research and translational applications. ProPure proteins help researchers reduce variability, improve reproducibility, and accelerate the development of next-generation cancer therapies.

 

SinoBiological June 2026 QR Code

Learn more about ProPure™ endotoxin-free proteins at sinobiological.com/category/endotoxin-free-proteins.

The post ProPure™ Endotoxin-Free Proteins for Reliable Cancer Research appeared first on Inside Precision Medicine.

Posted on

TARGA Imager Enables High-Resolution Imaging of Neurodevelopmental Models

Sponsored content brought to you by

Lumencor logo

Neurodevelopment in schizophrenia poses major challenges for experimental study due at least in part to the brain’s genetic complexity, cellular diversity, and limitations in accessing living human tissue. To overcome such barriers, researchers often use complementary human stem cell–derived models: adherent cortical organoids and Neurogenin-2 (NGN2) induced neurons. Adherent cortical organoids form three-dimensional cultures containing diverse cortical neuron types, enabling analysis of network development and long-term maturation over months.1 In contrast, NGN2 neurons generate rapid, two-dimensional, homogeneous populations of excitatory neurons that display robust activity within weeks, making them well suited for scalable, functional assays, and high-throughput screening.2

With the added insight that stem cell models offer into the neural development of the schizophrenic brain, the quantification of patient-derived neurons’ collective function is a priority.3 At Columbia University’s Mortimer B. Zuckerman Mind Brain and Behavior Institute, researchers use NGN2 neurons, yielding reproducible populations of excitatory cortical neurons that scale reliably across experiments.

Calcium imaging provides a powerful functional readout in these NGN2 neuron networks. When a neuron fires an action potential, voltage-gated calcium channels open and intracellular calcium rises sharply.4 Fluorescence calcium indicators convert transient, ionic changes into fluorescence emission that can be quantitatively detected via light microscopy across thousands of cells simultaneously. Coupling calcium-sensitive reporters with high-speed optical microscopy enables noninvasive, population-level measurement of neural activity, synchrony, and network dynamics. Interpreting these rich image sequences requires sophisticated theoretical and numerical approaches.5

Building on the ability to measure neural activity with calcium imaging at scale, Lumencor’s TARGA Imager represents a transformative step in the development of optical imaging hardware for the study of neurodevelopmental conditions such as schizophrenia. It is well suited to workflows where NGN2-neuron cultures are studied across multiple conditions in parallel (Figure 1). In these contexts, TARGA delivers calcium fluorescence images over millimeter-scale fields of view within standard 96-well plates, entire well areas, while maintaining high-speed, faster-than video rate imaging with precision resolution.

Lumencor NGN2-neurons calcium imaging workflow
Figure 1. TARGA implementation for NGN2-neurons calcium imaging workflow

These capabilities allow researchers to observe chemical communications across large neuronal networks rather than isolated cells in real time. Images can be acquired at frequencies up to 100 Hz, enabling capture of fast calcium transients of collective neuronal dynamics. Rapid switching of multicolor excitation light supports multiplexed fluorescence dyes, linking functional activity with cellular structure and organization.

Overall, TARGA achieves high spatial, temporal, and spectral resolution simultaneously with precise, automated opto-mechanical architecture. These data are well matched to modern image analysis and AI algorithms, generating robust fluorescence traces from complex neuronal populations (Figure 2). In combination, these features make the TARGA Imager a revelatory neuroscience tool, uniquely enabling visualization of emergent collective behavior at millimeter scale with exceptional resolution. Such integrated performance accelerates discovery by bridging cellular mechanisms and systems-level phenotypes relevant to schizophrenia pathophysiology and therapeutic screening. By uniting scale, speed, and precision in a single optical platform, TARGA empowers researchers to probe experimental neuroscience and strengthens translational studies of complex psychiatric disease at population scale.

NGN2-neurons calcium imaging workflow
Figure 1. TARGA implementation for NGN2-neurons calcium imaging workflow

 

References

  1. Van der Kroeg et al. Human adherent cortical organoids in a multiwell format. eLife. 2024. 13:e98340.
  2. Shan et al. Fully defined NGN2 neuron protocol reveals diverse signatures of neuronal maturation. Cell Reports Methods. 2024. 4:100858.
  3. Rao et al. Aberrant pace of cortical neuron development in brain organoids from patients with 22q11.2 deletion syndrome‑associated schizophrenia. Nature Communications. 2025. 16:6986.
  4. Zhang et al. Fast and sensitive GCaMP calcium indicators for imaging neural populations. Nature. 2023. 615:884–891.
  5. Pasarkar et al. maskNMF: A denoise‑sparsen‑detect approach for extracting neural signals from dense imaging data. bioRxiv. 2023. 2023.09.14.557777.

 

Lumencor_June 2026 sponsored content QRCode

 

To learn more, visit: lumencor.com or contact our team at: info@lumencor.com.

The post TARGA Imager Enables High-Resolution Imaging of Neurodevelopmental Models appeared first on Inside Precision Medicine.

Posted on

STAT+: Novo underwhelmed by drug it once fought Pfizer for

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Gene therapies can now cure disease, but America still hasn’t figured out how to pay for them. Is there a better way? Also, Novo executives are downplaying a once-coveted obesity drug, Incyte is making a $2 billion blood disease bet, and new data suggest Boehringer’s obesity contender may struggle to stand out in an increasingly crowded market.

The need-to-know this morning

  • Roche is partnering with Nurix Therapeutics to co-develop an experimental antibody treatment that works by degrading, or eliminating, a protein called BTK that is associated with blood cancer and other diseases. 
  • Treeline Biosciences, the developer of early-stage cancer medicines co-founded by biotech entrepreneur Josh Bilenker, is going public via a reverse merger with Standard BioTools. 

Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate

Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients.

Continue to STAT+ to read the full story…

Posted on

STAT+: Pharmalittle: We’re reading about Lilly and Pfizer obesity drug data, Roche and J&J deals, and more

Good morning, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating because that oh-too-familiar routine of meetings, deadlines, and the like has returned with a vengeance. You knew this would happen, yes? To cope, we are relying, as always, on cups of stimulation. Our choice today is laced with chocolate raspberry. Feel free to join us. Remember, no prescription is required. Meanwhile, here are some tidbits to help you along. Best of luck accomplishing your goals today, and of course, do keep in touch. …

Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients, but its next act — this time as a co-lead — was just revealed, STAT points out. Tango Therapeutics said that in an early-stage clinical trial, a combination of its drug vopimetostat and Revolution’s daraxonrasib led to durable responses in the large majority of pancreatic cancer patients who received both medicines. Tango’s strategy of testing the two targeted drugs is notable because combination approaches in pancreatic cancer often include chemotherapy. The recent successful Revolution trial that has upended the specialty tested daraxonrasib versus chemotherapy as a second-line treatment. 

Eli Lilly has already established that its next-generation obesity drug can lead to rapid weight loss, but researchers disclosed new data that provide more details on the safety and tolerability of the closely watched therapy, STAT writes. Lilly previously said that in one late-stage study, retatrutide helped people with diabetes lower blood sugar and lose a significant amount of weight, which is notable since those who have diabetes tend to lose less weight on treatment than those who do not. New data showed seven out of the 403 participants who received retatrutide experienced arrhythmias, and three treated participants experienced major cardiovascular complications, compared with none in the placebo group.

Continue to STAT+ to read the full story…

Posted on

Disruption of a GalR2–mitochondrial axis in the ventral hippocampus contributes to depression-like phenotypes after prenatal stress

BackgroundPrenatal stress (PS) is a major risk factor for depression later in life, yet the cellular mechanisms linking early-life adversity to long-term affective vulnerability remain incompletely understood. Neuropeptide receptors have emerged as important modulators of stress-related psychopathology, but their roles in mitochondrial regulation within limbic circuits remain largely unexplored.MethodsA rat model of PS was established to assess depression-like behaviors in adulthood. Mitochondrial ultrastructure, ATP production, and the expression of Galanin receptor 2 (GalR2) and key components of the PINK1/Parkin mitochondrial quality control machinery were examined in the ventral hippocampus (vHPC). The effects of intranasal administration of the GalR2 agonist AR-M1896 on behavioral and mitochondrial alterations were evaluated in vivo. To directly test whether the vHPC mediates these effects, we performed unilateral intra−vHPC infusion of AR−M1896. In vitro, glucocorticoid exposure and pharmacological manipulation of GalR2 were used to assess their impact on mitochondrial function and PINK1/Parkin signaling.ResultsPS induced persistent anhedonia-like behavior and behavioral despair phenotypes in adult offspring, accompanied by marked mitochondrial structural abnormalities, reduced ATP production, and downregulation of GalR2 and PINK1/Parkin-associated mitochondrial quality control signaling in the vHPC. Intranasal AR-M1896 partially normalized reward-related behavioral deficits and ameliorated mitochondrial dysfunction. Importantly, direct intra−vHPC infusion of AR−M1896 elevated ATP, PINK1 and Parkin levels in the ipsilateral vHPC, providing causal evidence that the vHPC is a critical site for GalR2−mediated PINK1/Parkin-related mitophagy−restoring effects. In cell-based assays, glucocorticoid exposure suppressed, whereas GalR2 activation enhanced, mitochondrial membrane potential and PINK1/Parkin-related signaling.ConclusionThese findings identify a GalR2–mitochondrial axis in the ventral hippocampus that is disrupted by PS and associated with vulnerability to depression-like phenotypes. The complementary intra−vHPC infusion experiments establish a causal role for vHPC GalR2 signaling in rescuing mitochondrial deficits, directly demonstrating that intranasal AR−M1896 acts at least in part via the vHPC. This receptor–organelle pathway may represent a neurobiological mechanism linking early-life adversity to long-term affective dysfunction.
Posted on

Effects of SGLT2 inhibition on incident heart failure in carriers of cardiomyopathy-associated genetic variants

Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04439-x

In a whole-exome sequencing analysis, the beneficial effects of the SGLT2 inhibitor dapagliflozin in reducing the risk of future heart failure hospitalization in individuals with type 2 diabetes were markedly greater in individuals who carried a cardiomyopathy-associated genetic variant compared with noncarriers, suggesting a personalized preventative therapy based on genetic information.

Posted on

Post-adjuvant chemotherapy in ctDNA-positive patients with resected colorectal cancer: a randomized phase 3 trial

Nature Medicine, Published online: 08 June 2026; doi:10.1038/s41591-026-04428-0

In the randomized, double-blind phase 3 ALTAIR trial, patients with resected colorectal cancer who became positive for circulating tumor DNA during post-adjuvant surveillance received trifluridine/tipiracil hydrochloride therapy, which did not significantly prolong disease-free survival compared with placebo.

Posted on

STAT+: Combination of pancreatic cancer drugs from Tango, Revolution leads to high response rate

Revolution Medicines’ experimental pancreatic cancer drug has been the star of the oncology field in recent weeks, with new data showing the medicine produced unprecedented outcomes for patients. 

Its next act — this time as a co-lead — was revealed Monday.

Tango Therapeutics said that in an early-stage clinical trial, a combination of its drug vopimetostat along with Revolution’s daraxonrasib led to a durable responses in the large majority of pancreatic cancer patients who received both medicines. 

Continue to STAT+ to read the full story…

Posted on

Survodutide in adults with obesity and metabolic dysfunction-associated steatotic liver disease: SYNCHRONIZE-MASLD, a randomized, double-blind, placebo-controlled phase 3 trial

Nature Medicine, Published online: 07 June 2026; doi:10.1038/s41591-026-04479-3

As presented at the American Diabetes Association Meeting, in this phase 3 trial, weekly subcutaneous injections of survodutide, a glucagon receptor/GLP-1R dual agonist, lowered liver fat content and body weight compared to placebo in adults with obesity and at-risk metabolic dysfunction-associated steatotic liver disease (MASLD).